Asymchem Laboratories (Tianjin) Co., Ltd. announced that it will operate the former Pfizer U.K. small molecule API pilot plant and part of the development laboratories through a new lease agreement between Asymchem and Discovery Park, establishing Asymchem?s first manufacturing footprint in Europe. Asymchem will continue to operate the site in Sandwich, Kent, as a clinical small molecule development and manufacturing facility to meet global client demands for pharma services and supply. The development laboratories are expected to begin operation in June 2024, followed by the API pilot plant in August.

The site is expected to employ approximately 100 individuals by the end of 2024, including many staff previously employed by Pfizer. Planned additions for the site include capabilities for the manufacture of peptides and oligonucleotides, as well as sustainability capabilities utilizing continuous flow and biocatalysis.